natgillin/translations-raw huggingface dataset:
The frequency category was estimated as the upper limit of the 95% confidence interval calculated on the basis of the total number of patients exposed to TCZ in clinical trials. 
Skupina pogostnosti je bila ocenjena kot zgornja meja 95-odstotnega intervala zaupanja, izračunana na podlagi skupnega števila bolnikov, izpostavljenih tocilizumabu v kliničnih preskušanjih.
Based upon the chronic nature of GCA, treatment beyond 52 weeks should be guided by disease activity, physician discretion, and patient choice. 
Glede na kronično naravo GCA je treba pri zdravljenju, daljšem od 52 tednov, upoštevati aktivnost bolezni, zdravnikovo presojo in bolnikove želje.
Patients were considered responders if CRS resolved within 14 days of the first dose of tocilizumab, if no more than 2 doses of RoActemra were needed, and no drugs other than RoActemra and corticosteroids were used for treatment. 
Bolniki so bili ocenjeni kot odzivni, če je CRS izzvenel v 14 dneh po prvem odmerku tocilizumaba, če nista bila potrebna več kot dva odmerka zdravila RoActemra in če za zdravljenje niso uporabili drugih zdravil kot zdravilo RoActemra in kortikosteroide.
The median time from start of CRS to first dose of tocilizumab was 3 days (range, 0-18 days). 
Mediani čas od pojava CRS do prvega odmerka tocilizumaba je bil 3 dni (razpon: 0 - 18 dni).
One event (angioedema) was considered serious and life-threatening, and the patient was discontinued from study treatment. 
(angioedem) so smatrali za resen ter življenje ogrožajoč in bolniku so študijsko zdravilo ukinili.
This patient did not develop a hypersensitivity reaction or injection site reaction. 
Ta bolnik ni imel preobčutljivostne reakcije ali reakcije na mestu injiciranja.
Approximately one-third of the patients in the GCA study had moderate renal impairment at baseline (estimated creatinine clearance of 30-59 mL/min). 
Približno tretjina bolnikov v študiji GCA je imela izhodiščno zmerno okvaro ledvic (ocenjeni očistek kreatinina od 30 do 59 ml/min).
• The product must not be given to patients with active or suspected infection 
• Zdravila se ne sme dajati bolnikom z aktivno okužbo ali pri sumu na okužbo.
ap value is adjusted for region and duration of RA for all endpoints and additionally baseline value for all continuous endpoints. 
a p vrednost je prilagojena glede na regijo in trajanje revmatoidnega artritisa za vse končne cilje ter dodatno za začetno vrednost pri vseh nadaljnjih končnih ciljih.
The accumulation ratio was higher for Cmin (2.49), which was expected based on the non-linear clearance contribution at lower concentrations. 
Delež je bil večji za Cmin (2,49), kar je pričakovano glede na nelinearen prispevek očistka pri nižjih koncentracijah.
The incidence of anti-tocilizumab antibody formation might be underestimated because of interference of tocilizumab with the assay and higher drug concentration observed in children compared to adults. 
Incidenca nastanka protiteles proti tocilizumabu je lahko podcenjena zaradi interference tocilizumaba z analizo in višje koncentracije zdravila, opažene pri otrocih v primerjavi z odraslimi.
• If you have cardiovascular risk factors such as raised blood pressure and raised cholesterol levels, tell your doctor. 
• Če imate srčno-žilne dejavnike tveganja, npr. zvišan krvni tlak ali zvišano koncentracijo holesterola, morate to povedati svojemu zdravniku.
All efficacy comparisons vs Placebo + MTX. 
Vse primerjave glede učinkovitosti so opravili s placebom + MTX.
Of the 4009 patients in this population, 3577 received treatment for at least 6 months, 3296 for at least one year, 2806 received treatment for at least 2 years and 1222 for 3 years. 
Od 4009 bolnikov v tej populaciji jih je 3577 zdravilo prejemalo vsaj 6 mesecev, 3296 vsaj 1 leto, 2806 vsaj 2 leti ter 1222 3 leta.
> 3 to 5 x ULN (confirmed by repeat testing, see section 4.4). 
> 3- do 5-kratna ZMN (potrjeno s ponovnim testiranjem, glejte poglavje 4.4).
The percent of patients achieving JIA ACR 30, 50, 70 and 90 responses are shown in Table 7. 
Odstotki bolnikov, ki so dosegli odzive JIA ACR 30, 50, 70 in 90 so prikazani v preglednici 7.
A place to prepare your supplies: • Find a well-lit, clean, flat surface such as a table 
Poiščite dobro osvetljeno, čisto in ravno površino, kot je miza.
The safety of subcutaneous RoActemra has been studied in one Phase III study (WA28119) with 251 GCA patients. 
Varnost subkutano uporabljenega zdravila RoActemra so raziskali v eni študiji III. faze (WA28119) pri 251 bolnikih z GCA.
Higher scores signal improvement in both FACIT-Fatigue and EQ5D. 
Višje ocene pomenijo izboljšanje tako po vprašaniku FACIT-Fatigue kot po vprašalniku EQ5D.
• If you have moderate to severe kidney function problems, your doctor will monitor you. 
• Če imate zmerne do hude težave z ledvičnim delovanjem, vas bo zdravnik nadzoroval.
RoActemra is indicated for the treatment of Giant Cell Arteritis (GCA) in adult patients. 
Zdravilo RoActemra je indicirano za zdravljenje gigantoceličnega arteriitisa (GCA) pri odraslih bolnikih.
• Do not speed up the warming process in any way, such as using the microwave or placing the pre-filled pen in warm water. 
• Na noben način ne pospešujte postopka ogrevanja in ga ne dajajte v mikrovalovno pečico ali toplo vodo.
If you still experience difficulty, you should consult your healthcare provider. 
Če imate še vedno težave, se posvetujte s svojim zdravstvenim delavcem.
Approximately 20% of patients had received prior treatment with DMARDs other than MTX. 
Približno 20 % bolnikov je prejelo predhodno zdravljenje z DMARD, z izjemo metotreksata.
Patients achieving a JIA ACR70 response were permitted corticosteroid dose reduction. 
Bolnikom, ki so dosegli odziv JIA ACR 70, so lahko zmanjšali odmerek kortikosteroida.
Side effects in children and adolescents with sJIA or pJIA are generally similar to those in adults. 
Neželeni učinki pri otrocih in mladostnikih s sJIA ali pJIA so na splošno podobni tistim pri odraslih.
Do not throw away used syringes or the puncture resistant container in household trash and do not recycle them. 
Ne zavrzite napolnjenih injekcijskih brizg ali zabojnika za ostre predmete v hišne smeti in jih ne reciklirajte.
Restart with 4 mg/kg or 8 mg/kg, as clinically appropriate 
Ponovno začnite s 4 mg/kg ali 8 mg/kg, kot je klinično ustrezno.
• Serious hypersensitivity reactions and their management 
• resne preobčutljivostne reakcije in njihovo obvladovanje,
The duration of glucocorticoid therapy during screening and before RoActemra (or placebo) was initiated, was similar in all 4 treatment groups (see Table 3). 
Trajanje zdravljenja z glukokortikoidi med presejanjem in pred uporabo zdravila RoActemra (ali placeba) je bilo podobno v vseh 4 zdravljenih skupinah (glejte preglednico 3).
Pack sizes of 1 and 4 vials. 
Pakiranja z 1 in 4 vialami.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with RoActemra should be made taking into account the benefit of breast-feeding to the child and the benefit of RoActemra therapy to the woman. 
Pri odločitvi za nadaljevanje ali prekinitev dojenja oz. za nadaljevanje ali prekinitev zdravljenja z zdravilom RoActemra je treba upoštevati korist dojenja za otroka in korist zdravljenja z zdravilom RoActemra za žensko.
• Never reattach the green cap after removal. 
• Zelenega pokrovčka po odstranitvi nikoli ne nameščajte ponovno.
In GCA patients, higher exposure was observed in patients with lower body weight. 
Pri bolnikih z GCA so zabeležili večjo izpostavljenost zdravilu pri bolnikih z manjšo telesno maso.
IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, monocytes and fibroblasts. 
IL-6 je pleiotropen proinflamatoren citokin, ki nastaja v različnih vrstah celic, med drugim v celicah T in B, monocitih in fibroblastih.
Cases of opportunistic infections have also been reported. 
Opisani so bili tudi primeri oportunističnih okužb.
Effects can include strokes and blindness. 
Zapleta bolezni sta lahko možganska kap in slepota.
PK differences are not accompanied by marked differences in PD parameters and so the clinical relevance is unknown. 
Farmakokinetičnih razlik ne spremljajo izrazite razlike farmakodinamičnih parametrov in tako klinični pomen ni znan.
After 12 weeks or at the time of switching to RoActemra, due to disease worsening, patients were treated in the open label extension phase. 
Po 12. tednih ali ob prehodu na zdravilo RoActemra zaradi poslabšanja bolezni so bolnike zdravili v odprti, podaljšani fazi.
• eye infection (conjunctivitis) 
• okužba oči (konjunktivitis),
• Watch the purple indicator until it stops moving to be sure the full dose of medication is injected. 
• Spremljajte vijolični indikator, dokler se ne ustavi, da se prepričate, da ste injicirali celoten odmerek zdravila.
• If you see drops of blood at the injection site, you can press a sterile cotton ball or gauze over the injection site for approximately 10 seconds. 
• Če na injekcijskem mestu opazite kapljice krvi, lahko nanj pritisnite sterilno vato ali gazo in držite približno 10 sekund.
If no clinical improvement in the signs and symptoms of CRS occurs after the first dose, up to 3 additional doses of RoActemra may be administered. 
Če po prvem odmerku ne pride do kliničnega izboljšanja znakov in simptomov CRS, je mogoče uporabiti do 3 dodatne odmerke zdravila RoActemra.
Important: Do not touch the needle shield which is located at the tip of the pre-filled pen below the Window area (see Figure A), to avoid accidental needle stick injury. 
Pomembno: Ne dotikajte se zaščite za iglo, ki se nahaja na konici napolnjenega injekcijskega peresnika pod okencem (glejte sliko A), da se izognete naključni poškodbi z iglo.
• Return any remaining pre-filled pens in the box to the refrigerator. 
• Vse preostale napolnjene injekcijske peresnike v škatli vrnite v hladilnik.
• You may hear a second “click” during the injection but you should continue to hold the pre filled pen firmly against your skin until the purple indicator stops moving. 
• Med injiciranjem lahko slišite drugi klik, vendar morate napolnjeni injekcijski peresnik še naprej trdno držati na koži, dokler se vijolični indikator ne ustavi.
The Patient's Global Assessment of disease activity was assessed on a 0-100mm Visual Analogue Scale (VAS). 
Bolnikovo celotno oceno aktivnosti bolezni so ocenili s pomočjo vizualne analogne lestvice (Visual Analogue Scale, VAS) od 0 do 100 mm.
In study II, 65% of patients achieved a DAS28 < 2.6 at week 104 compared to 48% at 52 weeks and 33% of patients at week 24. 
V študiji II je 65 % bolnikov doseglo DAS28 < 2,6 po 104 tednih v primerjavi z 48 % bolnikov po 52 tednih ter 33 % bolnikov po 24 tednih.
b Non-responder Imputation used for missing data. 
b Za manjkajoče podatke so uporabili imputacijo za neodzivne bolnike.
Patients would be monitored for liver function tests. 
Bolniki bodo opravljali teste delovanja jeter.
• increased bilirubin shown by blood tests 
• zvišanje vrednosti bilirubina v krvi, ki ga pokažejo preiskave krvi,
Serious hepatic injury occurred between 2 weeks to more than 5 years after initiation of RoActemra. 
Resna okvara jeter se je pojavila od 2 tednov do več kot 5 let po začetku zdravljenja z zdravilom RoActemra.
Available non-clinical data demonstrated the effect of IL-6 on malignant progression and apoptosis resistance to various cancer types. 
Razpoložljivi neklinični podatki so pri več različnih vrstah raka pokazali učinek IL-6 na napredovanje malignoma in odpornosti proti apoptozi.
Like all medicines, RoActemra can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo RoActemra neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
• There may be a little bleeding at the injection site. 
• Na mestu injiciranja se lahko pojavi manjša krvavitev.
The efficacy population for the tisagenlecleucel cohort included 28 males and 23 females (total 51 patients) of median age 17 years (range, 3-68 years). 
Populacija, v kateri so spremljali učinkovitost, je v kohorti s tisagenlecleucelom vključevala 28 moških in 23 žensk (skupaj 51 bolnikov) povprečne starosti 17 let (razpon: 3 - 68 let).
Read all of this leaflet carefully before you are given this medicine because it contains important information for you. 
Preden boste prejeli to zdravilo, natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
Patient advice regarding early recognition and treatment to limit risk of a serious infection 
Nasvet bolniku glede resnih okužb (zgodnjega prepoznavanja in zdravljenja za zmanjšanje tveganja njihovega nastanka)
• Risk of gastrointestinal perforations especially in patients with history of diverticulitis or intestinal ulcerations 
• tveganje za perforacije v prebavilih, posebno pri bolnikih z anamnezo divertikulitisa ali črevesnih ulceracij,
• low white blood cell counts shown by blood tests (neutropenia, leucopenia) 
• majhno število belih krvnih celic, ki ga pokažejo preiskave krvi (nevtropenija, levkopenija),
The all control population includes all patients from the double-blind phases of each core study from randomization until either the first change in the treatment regimen, or two years is reached. 
Vsa kontrolna populacija je vključila vse bolnike iz dvojno slepih faz vsake osnovne študije od randomizacije do dosežene prve spremembe v režimu zdravljenja ali do preteka dveh let.
You must press the plunger all the way down to ensure that you get the full dose of medication and to ensure the trigger fingers are completely pushed to the side. 
Bat morate pritisniti do konca, da boste zagotovo prejeli celoten odmerek zdravila in da bosta sprostitveni sponki popolnoma potisnjeni navzven.
Before you use the RoACTEMRA pre-filled pen for the first time, make sure your healthcare provider shows you the right way to use it. 
Preden prvič uporabite napolnjeni injekcijski peresnik zdravila RoACTEMRA, poskrbite, da vam zdravstveni delavec pokaže pravi način uporabe.
What RoActemra is and what it is used for 
Kaj je zdravilo RoActemra in za kaj ga uporabljamo
Give the injection 
Dajte injekcijo
At week 52 and week 104 the co-primary endpoints were prevention of joint damage and improvement in physical function. 
Po 52 tednih ter 104 tednih sta bila dodatna primarna cilja preprečitev okvare sklepov in izboljšanje funkcijske zmogljivosti.
The results from study SC-I is shown in Table 2. 
Rezultati iz študije SC-I so prikazani v preglednici 2.
Do not use the pre-filled pen if the box looks like it has already been opened. 
Ne uporabite napolnjenega injekcijskega peresnika, če je videti, da je bila škatla že odprta.
• headache, dizziness, high blood pressure 
• glavobol, omotica, visok krvni tlak,
No adverse reactions were observed. 
Opazili niso nobenih neželenih učinkov.
Allow the syringe to adjust to room temperature 
Pustite, da se napolnjena injekcijska brizga ogreje do sobne temperature
• 1 Sterile cotton ball or gauze 
• 1 sterilna bombažna kroglica ali gaza
• If you don't keep the needle-shield completely pushed against the skin, the green Activation button will not work. 
• Če zaščite za iglo popolnoma ne potisnete na kožo, se zeleni gumb za aktivacijo ne bo sprožil.
There are no adequate data from the use of tocilizumab in pregnant women. 
Ni zadostnih podatkov o uporabi tocilizumaba pri nosečnicah.
Reductions in corticosteroids continued, with 44 patients off oral corticosteroids at week 44, while maintaining JIA ACR responses. 
Zmanjšanja odmerkov kortikosteroidov so se nadaljevala, v 44. tednu peroralnih kortikosteroidov ni prejemalo 44 bolnikov, ki so ohranili odziv JIA ACR.
• allergic (hypersensitivity) reactions 
• alergijske (preobčutljivostne) reakcije,
Your healthcare provider should show you how to prepare and inject properly before you use the RoActemra syringe for the first time. 
Vaš zdravstveni delavec vam bo pokazal, kako ustrezno pripraviti in injicirati zdravilo, preden boste napolnjeno injekcijsko brizgo z zdravilom RoActemra prvič uporabili.
Study WA28119 was a randomized, multi-center, double-blind placebo-controlled Phase III superiority study conducted to assess the efficacy and safety of RoActemra in patients with GCA. 
Študija WA28119 je bila randomizirana, multicentrična, dvojno slepa, s placebom kontrolirana študija superiornosti III. faze za oceno učinkovitosti in varnosti zdravila RoActemra pri bolnikih s GCA.
The extent varies with the patient's body weight (increased in light body weight patients and decreased in heavy body weight patients) but clinical outcome is consistent with that observed in intravenous treated patients. 
Obseg se razlikuje glede na bolnikovo telesno maso (večji pri bolnikih z manjšo telesno maso in manjši pri bolnikih z večjo telesno maso), klinični izid pa je skladen z opaženim pri bolnikih, zdravljenih z intravensko obliko.
It should be clear and colorless to pale yellow. 
Biti mora bistra in brezbarvna do bledo rumena.
If you notice any of these, tell your doctor as soon as possible. 
Če opazite kar koli od naštetega, čim prej obvestite svojega zdravnika.
There have been postmarketing reports of interstitial lung disease (including pneumonitis and pulmonary fibrosis), some of which had fatal outcomes. 
Po prihodu zdravila na trg so poročali o intersticijski bolezni pljuč (vključno s pnevmonitisom in pljučno fibrozo), v nekaterih primerih s smrtnim izidom.
Severe neutropenia may be associated with an increased risk of serious infections, although there has been no clear association between decreases in neutrophils and the occurrence of serious infections in clinical trials with RoActemra to date. 
Huda nevtropenija je lahko povezana s povečanim tveganjem za hude okužbe, čeprav do sedaj v kliničnih preskušanjih z zdravilom RoActemra ni bilo jasne povezave med zmanjšanjem števila nevtrofilcev ter pojavom hudih okužb.
RoActemra can affect the way some medicines work, and the dose of these may require adjustment. 
RoActemra lahko vpliva na delovanje nekaterih zdravil in morda bo treba njihove odmerke prilagoditi.
IL-6 is involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, induction of hepatic acute phase protein synthesis and stimulation of haemopoiesis. 
IL-6 je vpleten v različna fiziološka dogajanja, npr. aktiviranje celic T, indukcijo sekrecije imunoglobulinov, indukcijo jetrne sinteze beljakovin akutne faze in stimulacijo hematopoeze.
• If your injection is given by another person, this person must also be careful when removing the pre-filled pen and disposing of it to prevent accidental needle stick injury and passing infection. 
• Če injiciranje opravlja druga oseba, mora biti tudi ta oseba previdna pri odlaganju in odstranjevanju napolnjenega injekcijskega peresnika, da prepreči nenamerno poškodbo z iglo in prenos okužbe.
These results are consistent with those observed in patients treated with intravenous RoActemra. 
Ti rezultati so skladni z opaženimi pri bolnikih, zdravljenih z intravenskim zdravilom
Continued therapy should be carefully reconsidered in a patient exhibiting no improvement within this timeframe. 
O nadaljevanju zdravljenja pri bolnikih, pri katerih v tem časovnem obdobju ni izboljšanja, je treba skrbno premisliti.
In the SC Study 5.8% [3/52] developed positive neutralizing anti-tocilizumab antibodies without developing a serious or clinically significant hypersensitivity reaction. 
V študiji s subkutano obliko so se pri 5,8 % [3/52] bolnikov pojavila pozitivna nevtralizirajoča protitelesa proti tocilizumabu brez razvoja resne ali klinično pomembne preobčutljivostne reakcije.
The double-blind controlled period was 6 months in four studies (studies I, III, IV and V) and was up to 2 years in one study (study II). 
Obdobje dvojno slepe kontrole je v štirih študijah (študije I, III, IV in V) trajalo 6 mesecev, v eni študiji pa do 2 leti (študija II).
The European Medicines Agency has waived the obligation to submit the results of studies with RoActemra in all subsets of the paediatric population in treatment of cytokine release syndrome associated with chimeric antigen receptor (CAR) T cell therapy. 
Evropska agencija za zdravila je opustila obvezo za oddajo rezultatov študij z zdravilom RoActemra v vseh podskupinah pediatrične populacije pri zdravljenju sindroma sproščanja citokinov, povezanega s terapijo s T-celicami s himernim antigenskim receptorjem (CAR).
Population pharmacokinetic analyses in any patient population tested so far indicate no relationship between apparent clearance and the presence of anti-drug antibodies. 
Populacijske farmakokinetične analize doslej v nobeni od testiranih populacij bolnikov niso pokazale razmerja med navideznim očistkom in prisotnostjo protiteles proti zdravilu.
In the majority of patients, there was no increase in atherogenic indices, and elevations in total cholesterol responded to treatment with lipid lowering agents. 
Pri večini bolnikov se aterogeni indeksi niso povečali in zvišanje celotnega holesterola se je odzvalo na zdravljenje s hipolipemiki.
Corticosteroid tapering was permitted from week six for patients who achieved a JIA ACR70 response. 
Prilagoditev odmerka kortikosteroidov je bila dovoljena od 6. tedna za bolnike, ki so dosegli odziv JIA ACR 70.
Do not attempt to administer an injection until you are sure that you understand how to use the RoActemra syringe. 
Ne poskušajte si dati injekcije, dokler niste prepričani, kako uporabljati napolnjeno injekcijsko brizgo RoActemra.
Doses above 1.2 g have not been evaluated in clinical studies (see section 5.1). 
V kliničnih študijah niso ocenili odmerkov, večjih od 1,2 g (glejte poglavje 5.1).
If any of these applies to you, tell the doctor or nurse giving you the infusion. 
Če se karkoli od naštetega nanaša na vas, obvestite zdravnika ali medicinsko sestro, ki vam bo dala infuzijo.
It is important to remain under your healthcare provider's care while using RoActemra. 
Pomembno je, da ostanete pod zdravniškim nadzorom, medtem ko uporabljate zdravilo RoActemra.
• skin infection (cellulitis) sometimes with fever and chills 
• okužba kože (celulitis), včasih z zvišano telesno temperaturo in mrzlico,
Patients transitioning from intravenous to subcutaneous formulation should administer their first subcutaneous dose instead of the next scheduled intravenous dose under the supervision of a qualified healthcare professional. 
Bolniki, ki preidejo z intravenske na subkutano obliko, morajo prejeti prvi subkutani odmerek namesto naslednjega načrtovanega intravenskega odmerka pod nadzorom usposobljenega zdravstvenega delavca.
• Low absolute neutrophil count (ANC) 
• Majhno absolutno število nevtrofilcev (absolute neutrophil count, ANC)
RoActemra should not be used during pregnancy unless clearly necessary. 
Zdravila RoActemra ne smete uporabljati med nosečnostjo, razen če je nujno potrebno.
Pharmacotherapeutic group: Immunosupressants, Interleukin inhibitors; ATC code: L04AC07. 
Farmakoterapevtska skupina: zdravila za zaviranje imunske odzivnosti, zaviralci interlevkinov; oznaka ATC: L04AC07.
In the open label extension phase (Part II), the overall rate of infections remained similar at 306.6 per 100 patient years. 
V odprti, podaljšani fazi (del II) je celokupen delež okužb ostal podoben in sicer 306,6 na 100
If a child has a history of macrophage activation syndrome (activation and uncontrolled proliferation of specific blood cells), tell your doctor. 
Če je otrok v preteklosti imel sindrom aktivacije makrofagov (aktivacijo in nekontrolirano razmnoževanje določene vrste krvnih celic), morate to povedati zdravniku.
Doses exceeding 800 mg per infusion are not recommended in CRS patients. 
Odmerki, ki presegajo 800 mg na infuzijo, pri bolnikih s CRS niso priporočljivi.
• The outer area of the upper arms may also be used only if the injection is being given by a caregiver. 
• Zunanji del nadlahti se za injiciranje lahko uporablja le, če vam injekcijo daje negovalec.
Thirty-nine patients (76.5%; 95% CI: 62.5%-87.2%) achieved a response. 
Odziv je doseglo 39 bolnikov (76,5 %, 95-% IZ: 62,5 % - 87,2 %).
• Do not hold or push on the plunger while inserting the needle into the skin. 
• Ne držite ali pritiskajte bata, ko vstavljate injekcijsko iglo v kožo.